David M. Spencer
Geen lopende functies
Profiel
David M.
Spencer was the founder of Bellicum Pharmaceuticals, Inc. founded in 2004, where he held the title of Chief Technology Officer from 2018 to 2019.
He also held the position of Professor and Vice Chairman-Pathology & Immunology at Baylor College of Medicine and was the Director & Chief Scientific Officer at Kiromic Biopharma, Inc. Dr. Spencer earned a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from the University of California San Diego.
Eerdere bekende functies van David M. Spencer
| Bedrijven | Functie | Einde |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Oprichter | 01-03-2019 |
| KIROMIC BIOPHARMA, INC. | Hoofd Techniek/Wetenschap/O&O | - |
| Baylor College of Medicine | Corporate Officer/Principal | - |
Opleiding van David M. Spencer
| Massachusetts Institute of Technology | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KIROMIC BIOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
